Drug Trial Radar · NCT02047981
Mortality Reduction After Oral Azithromycin: Mortality Study
Last checked: Nov 19, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
190,238
Actual
Start
Dec 2014
Primary completion
Sep 2018
Study completion Sep 2018
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bill and Melinda Gates Foundation; Johns Hopkins University; London School of Hygiene and Tropical Medicine
- First posted
- Jan 29, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 month, up to 60 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Our long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality. We propose a single multi-site (multi-country), cluster-randomized trial comparing communities randomized to oral azithromycin with those randomized to placebo. We hypothesize that mass azithromycin treatments will reduce childhood mortality.
Conditions
- Childhood Mortality
Interventions
AzithromycinDrug
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
PlaceboDrug
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause Mortality Rate in Children Aged 1-60 MonthsTime frame: 24 Months
- All-cause Mortality Rate in Children Aged 1-60 MonthsTime frame: 36 months
Locations
6 sites in 5 countries. Site status is shown where the registry gives one.
UCSF Proctor Foundation
San Francisco, California
Johns Hopkins University
Baltimore, Maryland
College of Medicine at the University of Malawi, Blantyre
Blantyre, Malawi
The Carter Center, Niger
Niamey, Niger
Kongwa Trachoma Project
Kongwa, Tanzania
London School of Hygiene & Tropical Medicine
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.